IceCure Medical Q2 Revenue Up ~45%, U.S. Footprint Expands ~70%
ICCM Icecure Medical Ltd
$3.11 -11.54%
View chart & analysis → 
- 1IceCure Medical (ICCM) Q2 revenue grew approximately 45% on increased system sales and higher usage of disposable probes.
- 2Its U.S. commercial footprint expanded around 70% following FDA early low-risk breast cancer authorization, with gross margin improving to 30%.
- 3The company holds about $12 million in cash and raised roughly $8.5 million during the quarter, projecting first patient enrollment in the CHOICE trial within 3–4 weeks.
This 3-line summary is compiled from the report below.
Moby +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다